Drug interactions in human neuropathic pain pharmacotherapy

Pain

Volumn 73, Issue 1, 1997, Pages 3-13

  Virani, Adil ^a   Mailis, Angela ^b   Shapiro, Lori E ^a   Shear, Neil H ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biotransformation; Cytochrome P450; Drug interactions; Metabolism; Neuropathic pain

Indexed keywords

AMITRIPTYLINE; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN; CYTOCHROME P450; DESIPRAMINE; ENCAINIDE; ERYTHROMYCIN; FLECAINIDE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; INDINAVIR; ISOENZYME; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; METOPROLOL; MIDAZOLAM; NIFEDIPINE; NORTRIPTYLINE; OMEPRAZOLE; PAROXETINE; PROPAFENONE; PROPRANOLOL; SERTRALINE; TERFENADINE; THEOPHYLLINE; UNINDEXED DRUG;

DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; PAIN; PRIORITY JOURNAL; REVIEW;

EID: 0030733093     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(97)00041-9     Document Type: Review

References (26)

1. Andersen, W.K. and Feingold, D.S., Adverse drug interactions clinically important for the dermatologist, Arch. Dermatol., 131 (1995) 468-473.
2. Backman, J.T., Olkkola, K.T., Ojala, M., Laaksovirta, H. and Neuvonen, P.J., Concentrations and effect of oral midazolam were greatly reduced in patients treated with carbamazepin or phenytoin, Epilepsia, 37 (1996) 253-257.
3. Benton, R., Honig, P., Zamani, K., Cantilena, L. and Woosley, R., Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram, Clin. Pharmacol. Ther., 59 (1996) 383-388.
4. Felsby, S., Nielsen, J., Arendt-Nielsen, L. and Jensen, T.S., NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride, Pain, 64 (1995) 283-291.
5. Gelenberg, A.J., The P450 family. Biological therapies in psychiatry, Department of Psychiatry Newsletter, University of Arizona Health Sciences Centre, Tucson, Arizona, 18 (8) (1995) 29-31.
6. Gibaldi, M., Drug interactions. Part II, Ann. Pharmacother., 26 (1992) 829-834.
7. Gracely, R.H., Price, D.D., Roberts, W.J. and Bennett, G.J., Qualitative sensory testing in patients with complex regional pain syndrome (CRPS) I and II. In: W. Jänig and M. Stanton-Hicks (Eds.), Reflex Sympathetic Dystrophy: A Reappraisal, Progress in Pain Research and Management, IASP Press, Seattle, 6 (1996) 151-172.
8. Honig, P.K., Wortham, D.C., Zamani, K., Conner, D.P., Mullin, J.C. and Cantilena, L.R., Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences, J. Am. Med. Assoc., 269 (1993) 1513-1518.
9. Kalant, H., Drug biotransformation. In: H. Kalant and W. Roschlau (Eds.), Principles of Medical Pharmacology, 5th edn., Chapter 4, B.C. Decker Inc., 1989, pp. 35-48.
10. Levy, R.H., Lane, E.A., Guyot, M., Brachet-Liermain, A., Cenraud, B. and Loiseau, P., Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man, Drug Metab. Dispos., 11 (1983) 286-294.
11. Mailis, A., Amani, N., Umana, M., Basur, R. and Roe, S., Effect of intravenous sodium amytal on cutaneous sensory abnormalities, spontaneous pain and algometric pain pressure thresholds in neuropathic pain patients: a placebo controlled study, Pain 70 (1997) 69-81.
12. Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J. and Cantilena, L.R., Torsades de Pointes occurring in association with terfenadine use, J. Am. Med. Assoc., 264 (1990) 2788-2790.
13. Murray, M., P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease, Clin. Pharmacokinet., 23 (1992) 132-146.
14. Nikolajsen, L., Hansen, C.L., Nielsen, J., Keller, J., Arendt-Nielsen, L. and Jensen, T.S., The effect of ketamine on phantom pain: a central neuropathic disorder maintained by peripheral input, Pain, 67 (1996) 69-77.
15. Parkinson, A., Biotransformation of xenobiotics. In: C.D. Klaassen (Ed.), Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn., McGraw-Hill, New York, 1996, p. 1111.
16. Persson, J., Axelsson, G., Hallin, R.G. and Gustafsson, L.L., Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization, Pain, 60 (1995) 217-222.
17. Price, D.D., Bennett, G.J. and Rafii, A., Psychophysiological observations on patients with neuropathic pain relieved by a sympathetic block, Pain, 36 (1989) 273-288.
18. Quinn, D.I. and Day, R.O., Drug interactions of clinical importance - an updated guide, Drug Saf., 12 (1995) 393-452.
19. Riddick, D.S., Drug biotransformation. In: H. Kalant and W. Roschlau (Eds.), Principles of Medical Pharmacology, 6th edn., Oxford University Press, New York, 1997 (in press).
20. Shapiro, L., Singer, M. and Shear, N.H., Pharmacokinetic mechanisms of drug-drug and drug-food interactions in dermatology. Curr. Opin. Dermatol. 1997; 4: (in press).
21. Shenfield, G.M., Oral contraceptives: are drug interactions of clinical significance?, Drug Saf., 9 (1993) 21-37.
22. Shulman, R.W., The serotonine syndrome: a tabular guide, Can. J. Clin. Pharmacol., 2 (1995) 139-144.
23. Slaughter, R.L. and Edwards, D.J., Recent advances: the cytochrome P450 enzymes, Ann. Pharmacother., 29 (1995) 619-624.
24. Tailor, S., Gupta, A., Walker, S. and Shear, N., Peripheral edema due to nifedipine-itraconazole interaction: a case report, Arch. Dermatol., 132 (1996) 350-352.
25. Timbrell, J.A., Principles of Biochemical Toxicology, 2nd edn., Taylor and Francis, London, 1991.
26. Watkins, P.B., Drug metabolism by cytochromes P450 in the liver and small bowel, Gastroenterol. Clin. North Am., 21 (1992) 511-526.